Dermatology and Therapy最新文献

筛选
英文 中文
Regulated Medical Waste Reduction in the Dermatology Clinic. 在皮肤科诊所减少受管制的医疗废物。
IF 3.5 3区 医学
Dermatology and Therapy Pub Date : 2024-11-01 Epub Date: 2024-10-10 DOI: 10.1007/s13555-024-01279-w
Divya K Sharma, Lilia C Murase, Misha Rosenbach, John S Barbieri, Jenny E Murase
{"title":"Regulated Medical Waste Reduction in the Dermatology Clinic.","authors":"Divya K Sharma, Lilia C Murase, Misha Rosenbach, John S Barbieri, Jenny E Murase","doi":"10.1007/s13555-024-01279-w","DOIUrl":"10.1007/s13555-024-01279-w","url":null,"abstract":"<p><strong>Introduction: </strong>The disposal of regulated medical waste (RMW) in the healthcare setting can be both costly and environmentally harmful. Prior studies have found large amounts of waste disposed of in RMW containers are inappropriately placed. Few studies to date have investigated the efficacy of waste reduction practices in the dermatology setting.</p><p><strong>Methods: </strong>This study aims to evaluate the effectiveness of a practice-wide intervention in reducing RMW in the outpatient dermatology setting. By performing daily waste audits and two concurrent educational interventions, the amount of RMW produced and percent of appropriately placed RMW will be measured. Further analysis will occur by comparing pre-intervention values to post-intervention values.</p><p><strong>Results: </strong>The percentage of waste properly placed in RMW containers prior to any intervention was 11%. Following both educational interventions, the percentage of waste properly placed in RMW containers increased by 56.1% (CI 43.7-68.5%) and the percentage of total waste produced that was identified and disposed of as RMW decreased by 6.0% (95% CI 1.2-10.8%).</p><p><strong>Conclusion: </strong>Our study provides practical data for dermatology providers to make small changes which can result in significant reductions of regulated medical waste, potentially providing benefits to the environment and cost-savings.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"3175-3181"},"PeriodicalIF":3.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11557808/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142399669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Publisher Correction: Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib. 出版商更正:重度脱发患者使用巴利昔尼可实现持续头皮毛发再生,其生活质量及焦虑和抑郁症状得到改善。
IF 3.5 3区 医学
Dermatology and Therapy Pub Date : 2024-11-01 DOI: 10.1007/s13555-024-01265-2
Brittany Craiglow, Yang Won Lee, Sergio Vañó-Galván, Alexander Egeberg, Yves Dutronc, Frederick Durand, Evangeline Pierce, Guanglei Yu, Yun-Fei Chen, Arash Mostaghimi
{"title":"Publisher Correction: Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib.","authors":"Brittany Craiglow, Yang Won Lee, Sergio Vañó-Galván, Alexander Egeberg, Yves Dutronc, Frederick Durand, Evangeline Pierce, Guanglei Yu, Yun-Fei Chen, Arash Mostaghimi","doi":"10.1007/s13555-024-01265-2","DOIUrl":"10.1007/s13555-024-01265-2","url":null,"abstract":"","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"3193"},"PeriodicalIF":3.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11557806/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Secukinumab in the Treatment of Psoriasis: A Narrative Review on Early Treatment and Real-World Evidence. 治疗银屑病的塞库单抗:关于早期治疗和现实世界证据的叙述性综述》。
IF 3.5 3区 医学
Dermatology and Therapy Pub Date : 2024-10-01 Epub Date: 2024-09-24 DOI: 10.1007/s13555-024-01255-4
Piergiorgio Malagoli, Paolo Dapavo, Paolo Amerio, Laura Atzori, Anna Balato, Federico Bardazzi, Luca Bianchi, Angelo Cattaneo, Andrea Chiricozzi, Maurizio Congedo, Maria Concetta Fargnoli, Claudia Giofrè, Paolo Gisondi, Claudio Guarneri, Serena Lembo, Francesco Loconsole, Giampiero Mazzocchetti, Santo Raffaele Mercuri, Pietro Morrone, Anna Maria Offidani, Giovanni Palazzo, Aurora Parodi, Giovanni Pellacani, Stefano Piaserico, Concetta Potenza, Francesca Prignano, Marco Romanelli, Paola Savoia, Luca Stingeni, Massimo Travaglini, Emanuele Trovato, Marina Venturini, Leonardo Zichichi, Antonio Costanzo
{"title":"Secukinumab in the Treatment of Psoriasis: A Narrative Review on Early Treatment and Real-World Evidence.","authors":"Piergiorgio Malagoli, Paolo Dapavo, Paolo Amerio, Laura Atzori, Anna Balato, Federico Bardazzi, Luca Bianchi, Angelo Cattaneo, Andrea Chiricozzi, Maurizio Congedo, Maria Concetta Fargnoli, Claudia Giofrè, Paolo Gisondi, Claudio Guarneri, Serena Lembo, Francesco Loconsole, Giampiero Mazzocchetti, Santo Raffaele Mercuri, Pietro Morrone, Anna Maria Offidani, Giovanni Palazzo, Aurora Parodi, Giovanni Pellacani, Stefano Piaserico, Concetta Potenza, Francesca Prignano, Marco Romanelli, Paola Savoia, Luca Stingeni, Massimo Travaglini, Emanuele Trovato, Marina Venturini, Leonardo Zichichi, Antonio Costanzo","doi":"10.1007/s13555-024-01255-4","DOIUrl":"10.1007/s13555-024-01255-4","url":null,"abstract":"<p><p>Psoriasis is a chronic, immune-mediated, inflammatory skin disease, associated with multiple comorbidities and psychological and psychiatric disorders. The quality of life of patients with this disease is severely compromised, especially in moderate-to-severe plaque psoriasis. Secukinumab, a fully humanized monoclonal antibody, was the first anti-interleukin (IL)-17 biologic approved for treating psoriasis. Secukinumab demonstrated long-lasting efficacy and a good safety profile in individuals with plaque psoriasis, and it is associated with an improvement in health-related quality of life. While there is evidence that early treatment with systemic therapy can affect disease progression and improve long-term outcomes in other autoimmune diseases, evidence is limited in psoriasis, especially in real-world settings. This review provides an overview of studies describing the effectiveness of secukinumab in the treatment of psoriasis summarizing the literature and focusing on real-world evidence and early intervention.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2739-2757"},"PeriodicalIF":3.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11480300/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142307280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Matching-Adjusted Indirect Comparison of the Efficacy and Safety of Difamilast 1% and Delgocitinib 0.5% in Patients with Moderate-to-Severe Atopic Dermatitis. 中重度特应性皮炎患者服用1%地拉米司特和地戈西替尼0.5%的疗效和安全性的匹配调整间接比较研究
IF 3.5 3区 医学
Dermatology and Therapy Pub Date : 2024-10-01 Epub Date: 2024-10-04 DOI: 10.1007/s13555-024-01282-1
Takeshi Nakahara, Hiroyuki Murota, Miyuki Matsukawa, Hiroe Takeda, Yilong Zhang, Tomohiro Kondo
{"title":"Matching-Adjusted Indirect Comparison of the Efficacy and Safety of Difamilast 1% and Delgocitinib 0.5% in Patients with Moderate-to-Severe Atopic Dermatitis.","authors":"Takeshi Nakahara, Hiroyuki Murota, Miyuki Matsukawa, Hiroe Takeda, Yilong Zhang, Tomohiro Kondo","doi":"10.1007/s13555-024-01282-1","DOIUrl":"10.1007/s13555-024-01282-1","url":null,"abstract":"<p><strong>Background: </strong>Atopic dermatitis (AD) is a chronic condition with an increasing incidence in Japan. Difamilast and delgocitinib are both new topical drugs for AD proven to be efficacious and safe in phases 2 and 3 clinical trials in Japan. However, there are no head-to-head trials comparing their efficacy and safety. The aim of this study was to determine the proportion of patients by severity and compare the clinical efficacy and safety of difamilast with delgocitinib among patients with moderate-to-severe AD using a matching-adjusted indirect comparison (MAIC).</p><p><strong>Methods: </strong>Phase 3 clinical trials of difamilast and delgocitinib for treating AD were included. The trials had similar designs but differed in baseline population characteristics. Anchored MAIC was used to align the baseline characteristics and calculate clinical outcomes. The primary outcome was to determine severity stages of the proportion of patients with AD through Eczema Area and Severity Index (EASI), while the secondary outcome included comparing other clinical efficacy and safety of difamilast with delgocitinib.</p><p><strong>Results: </strong>A total of 340 patients were selected (170 each received difamilast and placebo) from the difamilast trial, with 158 (106 received delgocitinib; 52 received placebo) from the delgocitinib trial for the analysis. After matching patients from the difamilast trial with those from the delgocitinib trial, the effective sample sizes (ESS) reduced to 32.7-43.3% of the original difamilast (treatment/placebo) patients. At week 4, the ESS in the difamilast group demonstrated no statistically significant differences in the distribution of AD severity stages, as per EASI scores, compared with the delgocitinib group. In addition, no significant differences were found in modified EASI (mEASI) scores, mEASI 50 and 75 scores, and safety outcomes between the two treatments.</p><p><strong>Conclusions: </strong>The anchored MAIC analysis indicates that difamilast treatment, like delgocitinib, is a useful option for the treatment of patients with moderate-to-severe AD in Japan.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2905-2916"},"PeriodicalIF":3.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11480269/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142375284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study. 更正:常规临床实践中用于治疗斑块状银屑病的赛妥珠单抗 Pegol:CIMREAL研究的一年结果。
IF 3.5 3区 医学
Dermatology and Therapy Pub Date : 2024-10-01 DOI: 10.1007/s13555-024-01271-4
Bernhard Korge, Olivier Vanhooteghem, Charles W Lynde, Alena Machovcova, Marc Perrussel, Elisavet Lazaridou, Claudio Marasca, David Vidal Sarro, Ines Duenas Pousa, Frederik Fierens, Paulette Williams, Saori Shimizu, Tanja Heidbrede, Richard B Warren
{"title":"Correction: Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study.","authors":"Bernhard Korge, Olivier Vanhooteghem, Charles W Lynde, Alena Machovcova, Marc Perrussel, Elisavet Lazaridou, Claudio Marasca, David Vidal Sarro, Ines Duenas Pousa, Frederik Fierens, Paulette Williams, Saori Shimizu, Tanja Heidbrede, Richard B Warren","doi":"10.1007/s13555-024-01271-4","DOIUrl":"10.1007/s13555-024-01271-4","url":null,"abstract":"","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2923-2926"},"PeriodicalIF":3.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11480265/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142343439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Descriptive, Post Hoc Analysis of Efficacy and Safety of Risankizumab in Diverse Racial and Ethnic Patient Populations With Moderate-to-Severe Psoriasis. 中度至重度银屑病患者中不同种族和人种利赞单抗疗效和安全性的描述性事后分析。
IF 3.5 3区 医学
Dermatology and Therapy Pub Date : 2024-10-01 Epub Date: 2024-10-02 DOI: 10.1007/s13555-024-01268-z
Andrew F Alexis, Melinda Gooderham, Shawn G Kwatra, Ahmad Amin, Susan Taylor, Ramon Espaillat, Trisha Rettig, Tianshuang Wu, Linyu Shi, Mark I Kaldas, Deanne M Dilley, Ranjeeta Sinvhal, Chudy Nduaka, Benjamin Lockshin
{"title":"A Descriptive, Post Hoc Analysis of Efficacy and Safety of Risankizumab in Diverse Racial and Ethnic Patient Populations With Moderate-to-Severe Psoriasis.","authors":"Andrew F Alexis, Melinda Gooderham, Shawn G Kwatra, Ahmad Amin, Susan Taylor, Ramon Espaillat, Trisha Rettig, Tianshuang Wu, Linyu Shi, Mark I Kaldas, Deanne M Dilley, Ranjeeta Sinvhal, Chudy Nduaka, Benjamin Lockshin","doi":"10.1007/s13555-024-01268-z","DOIUrl":"10.1007/s13555-024-01268-z","url":null,"abstract":"<p><strong>Introduction: </strong>Historically, patients with skin of color are underdiagnosed with psoriasis and underrepresented in clinical trials. In this study, we assess the efficacy and safety of risankizumab in patients with moderate-to-severe plaque psoriasis by race and ethnicity in the open label extension LIMMitless (NCT03047395).</p><p><strong>Methods: </strong>Patients received continuous treatment with 150 mg risankizumab through their initial trial and the open label extension. Patients self-identified their race and ethnicity. Efficacy was assessed using Psoriasis Area Severity Index (PASI) and Dermatology Life Quality Index (DLQI). Safety is reported by events/100 patient-years.</p><p><strong>Results: </strong>A total of 897 patients (race: 662 White, 196 Asian, 25 Black or African American, 14 Other; ethnicity: 98 Hispanic or Latino, 799 non-Hispanic or Latino) were included in this analysis. Compared to baseline, patients had a mean percent reduction in PASI between 94.6% (Asian) and 99.3% (Black or African American) and reported mean percent improvements in DLQI ranging from 87.1% (Asian and Black or African American) to 93.7% (Hispanic or Latino) at week 100.</p><p><strong>Conclusion: </strong>While the data presented here comprise a small retrospective descriptive analysis and cannot detect statistical differences, efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis appears similar across the racial and ethnic groups studied and no new safety signals were detected.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2877-2887"},"PeriodicalIF":3.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11480268/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142364774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: Consensus Recommendations for the Management of Atopic Dermatitis in the United Arab Emirates. 更正:阿拉伯联合酋长国特应性皮炎管理共识建议》。
IF 3.5 3区 医学
Dermatology and Therapy Pub Date : 2024-10-01 DOI: 10.1007/s13555-024-01276-z
Ahmed Ameen, Ahmed Al Dhaheri, Ashraf M Reda, Ayman Alnaeem, Fatima Al Marzooqi, Fatima Albreiki, Huda Rajab Ali, Hussein Abdel Dayem, Jawaher Alnaqbi, Mariam Al Zaabi, Mohammed Ahmed, Georg Stingl, Muna Al Murrawi
{"title":"Correction: Consensus Recommendations for the Management of Atopic Dermatitis in the United Arab Emirates.","authors":"Ahmed Ameen, Ahmed Al Dhaheri, Ashraf M Reda, Ayman Alnaeem, Fatima Al Marzooqi, Fatima Albreiki, Huda Rajab Ali, Hussein Abdel Dayem, Jawaher Alnaqbi, Mariam Al Zaabi, Mohammed Ahmed, Georg Stingl, Muna Al Murrawi","doi":"10.1007/s13555-024-01276-z","DOIUrl":"10.1007/s13555-024-01276-z","url":null,"abstract":"","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2927-2928"},"PeriodicalIF":3.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11480276/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142377772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advanced Systemic Treatments in Patients with Moderate-to-Severe Atopic Dermatitis: Key Learnings from Physicians Practicing in Nine Asian Countries and Territories. 中重度特应性皮炎患者的先进系统治疗:九个亚洲国家和地区执业医师的主要经验。
IF 3.5 3区 医学
Dermatology and Therapy Pub Date : 2024-10-01 Epub Date: 2024-09-28 DOI: 10.1007/s13555-024-01278-x
Chia-Yu Chu, Ramesh Bhat Marne, Christina Man-Tung Cheung, Le Ngoc Diep, Nopadon Noppakun, Endi Novianto, Maria Lourdes H Palmero, Yong-Kwang Tay, Azizan Noor Zalmy
{"title":"Advanced Systemic Treatments in Patients with Moderate-to-Severe Atopic Dermatitis: Key Learnings from Physicians Practicing in Nine Asian Countries and Territories.","authors":"Chia-Yu Chu, Ramesh Bhat Marne, Christina Man-Tung Cheung, Le Ngoc Diep, Nopadon Noppakun, Endi Novianto, Maria Lourdes H Palmero, Yong-Kwang Tay, Azizan Noor Zalmy","doi":"10.1007/s13555-024-01278-x","DOIUrl":"10.1007/s13555-024-01278-x","url":null,"abstract":"<p><strong>Introduction: </strong>Rapid progress made in the management of atopic dermatitis (AD) in recent years and the differences in patient journey between Asian and non-Asian populations call for a review of current atopic dermatitis landscape in Asia.</p><p><strong>Methods: </strong>A roundtable meeting with nine regional dermatological experts was held in June 2023 to discuss the optimal management approaches for moderate-to-severe AD, focusing on the use of advanced therapies.</p><p><strong>Results: </strong>Disease burden on patients' quality of life, treatment adherence, and financial constraints were identified as major concerns when managing patients with moderate-to-severe AD in parts of Asia. It was agreed that the Hanifin and Rajka's criteria or the UK Working Party's Diagnostic Criteria for Atopic Dermatitis can be used to guide the clinical diagnosis of AD. Meanwhile, patient-reported outcome scales including the Dermatology Life Quality Index and Atopic Dermatitis Control Tool can be used alongside depression monitoring scales to monitor treatment outcomes in patients with AD, allowing a better understanding for individualized treatment. When managing moderate-to-severe AD, phototherapy should be attempted after failure with topical treatments, followed by conventional disease-modifying antirheumatic drugs and, subsequently, biologics or Janus kinase inhibitors. Systemic corticosteroids can be used as short-term therapy for acute flares. Although these advanced treatments are known to be effective, physicians have to take into consideration safety concerns and limitations when prescribing these treatments.</p><p><strong>Conclusions: </strong>Treatments in AD have evolved and its management varies country by country. Unique challenges across Asian countries necessitate a different management approach in Asian patients with AD.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2669-2691"},"PeriodicalIF":3.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11480307/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142343438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comprehensive Codified Algorithms to Identify the Underestimated Burden of Hidradenitis Suppurativa in the United States. 综合编纂算法,确定美国被低估的化脓性扁桃体炎负担。
IF 3.5 3区 医学
Dermatology and Therapy Pub Date : 2024-10-01 Epub Date: 2024-09-24 DOI: 10.1007/s13555-024-01259-0
John R Ingram, Yvonne Geissbühler, John Darcy, Stephen Foley, Alex Gaffney, Aine McConnon, Craig Richardson, Amit Garg
{"title":"Comprehensive Codified Algorithms to Identify the Underestimated Burden of Hidradenitis Suppurativa in the United States.","authors":"John R Ingram, Yvonne Geissbühler, John Darcy, Stephen Foley, Alex Gaffney, Aine McConnon, Craig Richardson, Amit Garg","doi":"10.1007/s13555-024-01259-0","DOIUrl":"10.1007/s13555-024-01259-0","url":null,"abstract":"<p><strong>Introduction: </strong>Hidradenitis suppurativa (HS) is a painful, inflammatory skin disease associated with a high disease burden and long diagnostic delay. Prevalence estimates of HS vary widely in the literature owing to differing estimation methodologies. This study aimed to apply stepwise algorithms to estimate the prevalence of possible/diagnosed cases of HS in the US.</p><p><strong>Methods: </strong>This was a retrospective cohort study in adult and pediatric patients with HS which utilized data from four US databases (MarketScan [Medicare and Medicaid] and Optum [electronic health record (EHR) and Clinformatics Data Mart (CDM)]). Patients with possible/diagnosed HS were identified using two algorithms (termed Algorithm 1 and Algorithm 2), which assessed symptoms such as multiple skin boils in site-specific areas based on international classification of disease (ICD) codes. Patients with diagnosed HS were defined as having ≥ 2 outpatient or ≥ 1 inpatient diagnosis codes of HS. In each database, patients with continuous medical and pharmacy benefits in the 365 days pre-index and 0-365 days post-index periods were eligible for inclusion.</p><p><strong>Results: </strong>Across all databases, Algorithm 2 (MarketScan Medicare [N = 309,916]; MarketScan Medicaid [N = 188,783]; Optum EHR [N = 366,158]; Optum CDM [N = 173,812]) identified more patients with possible/diagnosed HS than Algorithm 1 (MarketScan Medicare [N = 194,353]; MarketScan Medicaid [N = 99,276]; Optum EHR [N = 177,957]; Optum CDM [N = 112,244]). Based on ICD-9/10 codes, the 5-year period prevalence of HS ranged from 0.06% to 0.12% across all databases, while for Algorithm 1 and Algorithm 2, this ranged from 0.27% to 0.41% and 0.49% to 0.78%, respectively. Adults and females generally had a higher 5-year period prevalence versus pediatric patients and males, respectively.</p><p><strong>Conclusion: </strong>This real-world study highlights that HS diagnosis codes alone may be insufficient to estimate the prevalence of HS, demonstrating the value of employing algorithms in practice which assess for parameters such as multiple skin boils in site-specific areas. Integrating robust methods to identify the prevalence of HS may improve the diagnostic delay observed in HS and improve treatment outcomes.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2859-2876"},"PeriodicalIF":3.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11480298/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142307279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Demographics, Disease Characteristics, and Time to Effective Treatment of Patients with Psoriasis in the Ghent PsoPlus Cohort of 2021. 2021 年根特 PsoPlus 队列中银屑病患者的人口统计、疾病特征和有效治疗时间。
IF 3.5 3区 医学
Dermatology and Therapy Pub Date : 2024-10-01 Epub Date: 2024-10-04 DOI: 10.1007/s13555-024-01277-y
Evelyn Meulewaeter, Anke Eylenbosch, Evelien Verhaeghe, Rani Soenen, Jo Lambert
{"title":"Demographics, Disease Characteristics, and Time to Effective Treatment of Patients with Psoriasis in the Ghent PsoPlus Cohort of 2021.","authors":"Evelyn Meulewaeter, Anke Eylenbosch, Evelien Verhaeghe, Rani Soenen, Jo Lambert","doi":"10.1007/s13555-024-01277-y","DOIUrl":"10.1007/s13555-024-01277-y","url":null,"abstract":"<p><strong>Introduction: </strong>Psoriasis is a chronic immune-mediated skin disease with several comorbidities and a considerable influence on quality of life. Many patients with moderate-to-severe psoriasis are undertreated and have a substantial disease duration before effective treatment is started. This study analyzed patient and disease characteristics and time to effective treatment of patients with psoriasis who consulted PsoPlus. It also examined whether a treat-to-target (T2T) approach, which is implemented in PsoPlus, has an impact on treatment choice and disease progression.</p><p><strong>Methods: </strong>Through a single center, retrospective study, 170 patients in the PsoPlus dedicated clinic were compared at moment of enrollment in PsoPlus and at the last recorded consultation in 2021.</p><p><strong>Results: </strong>Median disease duration at the first PsoPlus consultation was 16.0 (interquartile range (IQR) 19.0) years. There was a significant difference in Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) between the first and the last recorded PsoPlus consultation (PASI 6.0 (IQR 6.4) vs. 0.6 (IQR 2.6); DLQI 11 (IQR 11) vs. 2 (IQR 6); p < 0.001). A weak positive Spearman correlation (r<sub>s</sub>) was found between disease duration and PASI at the first PsoPlus consultation (r<sub>s</sub> = 0.175; p = 0.034), while a weak negative correlation (r<sub>s</sub> = - 0.2; p = 0.013) was found at the last registered PsoPlus consultation. Patients with a disease duration of more than 20 years had significantly more switches of treatment than those with a shorter disease duration (p < 0.001). Median time from psoriasis onset until PASI ≤ 2 was 16.0 years. Median time from the first PsoPlus consultation until PASI ≤ 2 was 7.0 months.</p><p><strong>Conclusion: </strong>The PsoPlus program with its T2T approach effectively improves clinical outcomes and quality of life for patients with psoriasis in a relatively short period, emphasizing the value of a structured, personalized treatment plan for long-term management.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2889-2903"},"PeriodicalIF":3.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11480273/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142371246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信